Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Pgoxin (P-gp Substrates), Rosuvastatin Calcium (BCRP and OATP1B1/1B3 Substrates) and Metformin Hydrochloride (MATE1/2-K Substrates) in Prostate Cancer Patients

NCT04621669 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT04621669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04621669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Pgoxin (P-gp Substrates), Rosuvastatin Calcium (BCRP and OATP1B1/1B3 Substrates) and Metformin Hydrochloride (MATE1/2-K Substrates) in Prostate Cancer Patients
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 8, 2021
Completion date
September 8, 2021
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-drug interaction,shr3680